Dynamics of HIV-1 replication following influenza vaccination of HIV+ individuals

Røsok, Bård I.; Voltersvik, Pål; Bjerknes, Robert; Axelsson, Maria; Haaheim, Lars R.; Åsjö, Birgitta

doi:10.1046/j.1365-2249.1996.25732.x

Cited by 55 publications

(28 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…18 The antibody response was evaluated according to the parameters set out by the European Medicines Evaluation Agency (EMEA) for subjects aged between 18 and 60 years and comprising a geometric mean titre (GMT) T 30 /T 0 ratio ≥ 2.5, seroconversion ≥ 40%, and postvaccine seroprotection ≥ 70%. 19 Seroconversion was defined as the onset of a titre in negative subjects or an increase of at least four-fold in the antibody titre between T 0 and T 30 . Seroprotection was defined as an antibody titre ≥ 1:40.…”

Section: Immunogenicitymentioning

confidence: 99%

“…Mean lymphocyte counts before vaccination (T 0 ), at 30 days (T 30 ) and 180 days (T 180 ) after immunization, divided according to the classification categories defined by the CDC, are shown in Table 2. Between-group comparisons of the lymphocyte counts at different observation times (T 0 versus T 30 and T 0 versus T 180 ) failed to reveal any statistically significant changes, with the exception of subjects with lymphocyte counts < 200 cells/mm 3 , vaccinated with conventional subunit vaccine, whose counts showed a progressive increase after immunization (P = 0.048).…”

Section: Cd4+ T-lymphocyte Countmentioning

confidence: 99%

“…Safety was assessed by evaluating the effect of vaccination on plasma levels of viraemia (HIV-1 RNA) and the CD4+ T-lymphocyte count. Venous blood samples were collected at the time of vaccination (T 0 ) and then 30 (T 30 ) and 180 (T 180 ) days after administration of the vaccine in order to assess immunogenicity and to evaluate the CD4+ T-lymphocyte count and level of viraemia (HIV-1 RNA).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Safety and Immunogenicity of Conventional Subunit and MF59-adjuvanted Influenza Vaccines in Human Immunodeficiency Virus-1-seropositive Patients

et al. 2005

View full text Add to dashboard Cite

In this study of influenza vaccination, 37 human immunodeficiency virus (HIV)-1-seropositive patients were randomized to receive either a vaccine with a conventional subunit or one adjuvanted with MF59. Blood samples were collected at the time of vaccination, and then 30 and 180 days later, to evaluate immunogenicity, CD4+ T-lymphocyte count and HIV-1 RNA levels. Seroconversion rates against the three viral strains included in the vaccine ranged between 44% and 72% and 53% and 68% for the adjuvanted vaccine and the subunit vaccine, respectively. Other criteria of the European Medicines Evaluation Agency were also met. Vaccination was not associated with serious adverse events. Local and systemic effects were mild and of short duration. CD4+ T-lymphocyte counts and viraemia levels were not negatively affected by vaccination. These results confirmed the safety and immunogenicity of these currently available vaccines in HIV-1-seropositive patients, thus supporting the recommendation for influenza immunization in this high-risk category.

show abstract

Section: Immunogenicitymentioning

confidence: 99%

Section: Cd4+ T-lymphocyte Countmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Safety and Immunogenicity of Conventional Subunit and MF59-adjuvanted Influenza Vaccines in Human Immunodeficiency Virus-1-seropositive Patients

et al. 2005

View full text Add to dashboard Cite

show abstract

“…In patients infected with flu virus, viral replication is occurring on the mucosal surface of respiratory tracts and virions are also found in mucosa-associated lymphoid tissue that is also one of the natural reservoir of HIV-1 (32-34), therefore suggesting the possible co-localization of both pathogens at the same site. Although previous studies have indicated that influenza vaccination could increase HIV-1 viral loads (35,36), a recent study has indicated that influenza infection did not alter HIV-1 viral load or the rate of CD4ϩ T cell decline or clinical progression (37). However, no study has directly addressed the role of flu-derived NA on the HIV-1 replicative cycle.…”

mentioning

confidence: 99%

Syncytium Formation and HIV-1 Replication Are Both Accentuated by Purified Influenza and Virus-associated Neuraminidase

Sun¹,

Barbeau²,

Sato³

et al. 2002

Journal of Biological Chemistry

View full text Add to dashboard Cite

show abstract

“…A vacinação por agentes que possuem antígenos dependentes do linfócito T, como é o caso da vacina contra a influenza com vírus inativados, pode levar, teoricamente, a um aumento na replicação do HIV, com infecção de novas células, resultando em uma maior destruição celular, podendo, por isso, ser até prejudicial ao organismo [7][8][9] .…”

unclassified

Vacinação contra influenza em crianças infectadas pelo HIV: alterações imunológicas e na carga viral

Carvalho¹,

Dutra²,

Tonelli³

2003

J. Pediatr. (Rio J.)

View full text Add to dashboard Cite

ResumoObjetivo: verificar se a vacinação contra influenza em crianças infectadas pelo HIV aumentaria a carga viral e reduziria os linfócitos T CD4+, conseqüentes à ativação da imunidade com antígenos dependentes do linfócito T.Métodos: estudo prospectivo descritivo, com 51 crianças infectadas pelo HIV, vacinadas contra influenza em 1999, em Florianó-polis, Brasil. Coletaram-se amostras de sangue no dia da vacinação, 14 a 20 e 60 a 90 dias após, para determinação dos níveis da carga viral do HIV e de linfócitos T CD4+. A análise estatística constou dos testes ANOVA de Friedman, t de Student para amostras dependentes, Correção de Bonferroni e Wilcoxon.Resultados: a média de idade foi de 6,08 anos (1 a 12,9 anos). A mediana da contagem de linfócitos T CD4+ no dia da vacinação e nos dois momentos subseqüentes foi de 789, 645 e 768 células/mm 3 . Observou-se redução significativa na contagem de linfócitos T CD4+ entre a primeira e a segunda determinação (p=0,0001, teste de Wilcoxon), o mesmo não ocorrendo entre a primeira e a terceira . Não houve diferença significativa nas porcentagens de linfócitos T CD4+ entre a primeira aferição e a segunda. A mediana da carga viral em log 10 cópias/ml foi de 4,38, 4,30 e 4,25, nos três momentos, respectivamente. Oito de 44 pacientes (18,2%) evidenciaram elevação >0,5 log 10 cópias/ml na carga viral entre a primeira e segunda aferição, quatro dos quais retornaram aos níveis basais na terceira.Conclusões: não se observou alteração significativa na porcentagem de linfócitos T CD4+, apesar de ocorrer elevação da carga viral do HIV, de forma transitória, após vacinação contra influenza. Recomenda-se uma certa prudência na aplicação da vacina contra influenza para as crianças com condição clínica e imunológica não estável, principalmente se essas não estiverem sob terapêutica antiretroviral eficaz.J Pediatr (Rio J) 2003;79(1):29-40: influenza, vacina contra influenza, infecção pelo HIV, carga viral do HIV, níveis de linfócitos T CD4+. AbstractObjective: to identify whether influenza immunization in HIV infected children could increase HIV viral load and decrease CD4+ lymphocytes count as a consequence of the response induced by a T cell-dependent antigen.Methods: prospective, descriptive study, with 51 HIV infected children, vaccinated against influenza in 1999, in Florianópolis, Brazil. Blood samples were collected at three different moments: on the immunization day; between 14 and 20 days later; between 60 and 90 days later. Plasma levels of HIV viral load and CD4+ lymphocytes count were determined. Friedman ANOVA test, Student t-test for dependent samples, Bonferroni correction, and Wilcoxon matched test were performed for statistic analysis.

show abstract

Dynamics of HIV-1 replication following influenza vaccination of HIV+ individuals

Cited by 55 publications

References 18 publications

Safety and Immunogenicity of Conventional Subunit and MF59-adjuvanted Influenza Vaccines in Human Immunodeficiency Virus-1-seropositive Patients

Safety and Immunogenicity of Conventional Subunit and MF59-adjuvanted Influenza Vaccines in Human Immunodeficiency Virus-1-seropositive Patients

Syncytium Formation and HIV-1 Replication Are Both Accentuated by Purified Influenza and Virus-associated Neuraminidase

Vacinação contra influenza em crianças infectadas pelo HIV: alterações imunológicas e na carga viral

Contact Info

Product

Resources

About